GLP-1 gets most of the attention in obesity drug coverage, but a second natural hormone, amylin, has quietly become just as important to where the field is headed next. Several of the most closely watched obesity drugs in development, discussed elsewhere on this site, work by targeting amylin's receptor either alone or alongside GLP-1's.

What Amylin Is

Amylin is a hormone made and released by the same pancreatic beta cells that produce insulin, and the two are co-secreted together after meals. Amylin's natural job is to help regulate blood sugar and appetite in ways that complement, rather than duplicate, insulin's role: it slows gastric emptying, promotes a feeling of fullness, and suppresses glucagon, a hormone that otherwise raises blood sugar by signaling the liver to release stored glucose.

How It Differs From GLP-1

Amylin and GLP-1 are structurally distinct hormones that act on separate receptors, even though their downstream effects, slower digestion and reduced appetite chief among them, overlap substantially. That overlap is exactly why researchers have become interested in targeting both pathways at once: because amylin and GLP-1 signal through different receptors, combining an amylin-pathway drug with a GLP-1 drug can produce additive effects on weight and blood sugar rather than simply duplicating the same mechanism twice. Some early research also suggests amylin-pathway activation may help preserve lean muscle mass better than GLP-1 activation alone during weight loss, though this remains an active area of study rather than a settled finding.

The First Approved Amylin Drug

Pramlintide, sold under the brand name Symlin and covered in more detail in this site's dedicated guide, was the first and remains the only FDA-approved amylin analog. It's approved as an add-on to insulin therapy for people with type 1 or type 2 diabetes, not for weight loss, and it requires separate injections from insulin rather than being combined into a single product.

The Current Wave of Amylin-Pathway Candidates

The more recent amylin story is almost entirely about obesity, not diabetes, and almost entirely still investigational. Cagrilintide, a longer-acting amylin analog from Novo Nordisk, is being developed both on its own and combined with semaglutide as CagriSema, covered in this site's guide to that combination. Eli Lilly's eloralintide takes a more selective approach, targeting the amylin receptor specifically rather than the related calcitonin receptor that some amylin analogs also engage, with the aim of reducing gastrointestinal side effects. Zealand Pharma's petrelintide is pursuing a similar selective-amylin strategy and has advanced into Phase 3 trials. Novo Nordisk has also developed a single molecule, zenagamtide, formerly known as amycretin and covered in this site's dedicated guide, designed to activate both the GLP-1 and amylin receptors from one drug rather than requiring two separate products.

What the Evidence Actually Shows

Unlike many of the research-chemical peptides this site covers, amylin-pathway obesity candidates are being tested in registered, controlled human clinical trials, not just animal studies, and several have reported Phase 2 or Phase 3 data. That's a meaningfully stronger evidence base than compounds like BPC-157 or TB-500, which remain almost entirely confined to preclinical research. Still, "in human trials" is not the same as "FDA-approved for obesity." None of these amylin-pathway obesity candidates, including cagrilintide, eloralintide, petrelintide, and zenagamtide, currently have FDA approval for weight management. Pramlintide's approval remains limited to its original diabetes indication.

The Bottom Line

Amylin is a natural hormone that works alongside GLP-1 rather than duplicating it, and pairing the two pathways has become one of the most active strategies in obesity drug development. The approach has real, growing human trial data behind it, which sets it apart from many research-chemical peptides, but as of today every amylin-pathway obesity candidate beyond pramlintide's original diabetes approval remains investigational. Anyone interested in these drugs should talk to a licensed physician about what's actually approved and available today, rather than what's still in trials.